CD274 and neoplasm: ICI immunotherapy using PD-L1 antibody has fewer side effects and better results than the existing chemotherapy drugs, however the use of aPD-L1 has decreased efficacy and tumor resistance limitations due to various reasons [32–34], including activation of neutrophils and reduction of cytotoxic T-lymphocytes by neutrophils [35–37].